Semaglutide is gaining traction as a novel treatment for chronic diseases. This manufactured glucagon-like peptide-1 (GLP-1) receptor agonist acts upon stimulating the pancreas to produce more insulin and suppressing glucagon production. Furthermore, semaglutide exhibits potential applica

Semaglutide has gained significant traction in recent years as a medication for treating type 2 diabetes and obesity. This powerful glucagon-like peptide-1 (GLP-1) receptor agonist works by mimicking the effects of a naturally occurring hormone in the body, promoting insulin secretion . U